Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodesix, Inc. stock logo
BDSX
Biodesix
$15.06
+1.8%
$14.08
$5.00
$20.21
$153.27M0.5942,970 shs21,089 shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$4.70
-4.1%
$4.36
$2.56
$15.84
$236.98M1.98819,082 shs771,157 shs
KindlyMD, Inc. stock logo
NAKA
KindlyMD
$4.32
-3.4%
$7.20
$4.05
$679.20
$77.79M15.84454,950 shs259,978 shs
Exagen Inc. stock logo
XGN
Exagen
$4.67
+4.2%
$3.64
$2.59
$12.23
$108.24M2.02401,624 shs145,515 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodesix, Inc. stock logo
BDSX
Biodesix
+1.76%-2.59%+2.87%-15.77%+135.61%
LifeMD, Inc. stock logo
LFMD
LifeMD
-4.08%-3.89%+3.52%+18.09%-62.79%
KindlyMD, Inc. stock logo
NAKA
KindlyMD
-3.36%+0.23%-36.40%-58.27%-99.41%
Exagen Inc. stock logo
XGN
Exagen
+4.24%+8.86%+34.58%+52.12%-35.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodesix, Inc. stock logo
BDSX
Biodesix
$15.06
+1.8%
$14.08
$5.00
$20.21
$153.27M0.5942,970 shs21,089 shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$4.70
-4.1%
$4.36
$2.56
$15.84
$236.98M1.98819,082 shs771,157 shs
KindlyMD, Inc. stock logo
NAKA
KindlyMD
$4.32
-3.4%
$7.20
$4.05
$679.20
$77.79M15.84454,950 shs259,978 shs
Exagen Inc. stock logo
XGN
Exagen
$4.67
+4.2%
$3.64
$2.59
$12.23
$108.24M2.02401,624 shs145,515 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodesix, Inc. stock logo
BDSX
Biodesix
+1.76%-2.59%+2.87%-15.77%+135.61%
LifeMD, Inc. stock logo
LFMD
LifeMD
-4.08%-3.89%+3.52%+18.09%-62.79%
KindlyMD, Inc. stock logo
NAKA
KindlyMD
-3.36%+0.23%-36.40%-58.27%-99.41%
Exagen Inc. stock logo
XGN
Exagen
+4.24%+8.86%+34.58%+52.12%-35.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biodesix, Inc. stock logo
BDSX
Biodesix
2.33
Hold$22.0046.08% Upside
LifeMD, Inc. stock logo
LFMD
LifeMD
2.70
Moderate Buy$9.1494.53% Upside
KindlyMD, Inc. stock logo
NAKA
KindlyMD
2.40
Hold$30.00594.44% Upside
Exagen Inc. stock logo
XGN
Exagen
2.78
Moderate Buy$9.2598.07% Upside

Current Analyst Ratings Breakdown

Latest NAKA, LFMD, BDSX, and XGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2026
LifeMD, Inc. stock logo
LFMD
LifeMD
Reiterated RatingBuy
5/26/2026
LifeMD, Inc. stock logo
LFMD
LifeMD
Reiterated RatingBuy$10.00
5/18/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
DowngradeSell (D-)Sell (E+)
5/12/2026
Exagen Inc. stock logo
XGN
Exagen
DowngradeSell (D-)Sell (E+)
5/12/2026
Exagen Inc. stock logo
XGN
Exagen
Lower Price TargetBuy$9.00 ➝ $8.00
5/11/2026
KindlyMD, Inc. stock logo
NAKA
KindlyMD
UpgradeSell (E+)Sell (D-)
5/7/2026
LifeMD, Inc. stock logo
LFMD
LifeMD
UpgradeSell (E+)Sell (D)
5/5/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
Boost Price TargetBuy$20.00 ➝ $22.00
5/4/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
Reiterated RatingSell (D-)
5/4/2026
LifeMD, Inc. stock logo
LFMD
LifeMD
Reiterated RatingBuy$10.00
4/27/2026
Exagen Inc. stock logo
XGN
Exagen
UpgradeSell (E+)Sell (D-)
(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biodesix, Inc. stock logo
BDSX
Biodesix
$88.50M1.76N/AN/A($0.31) per share-48.58
LifeMD, Inc. stock logo
LFMD
LifeMD
$194.05M1.17N/AN/A$0.48 per share9.79
KindlyMD, Inc. stock logo
NAKA
KindlyMD
$1.82M41.30N/AN/A$46.97 per share0.09
Exagen Inc. stock logo
XGN
Exagen
$66.57M1.69N/AN/A$0.77 per share6.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biodesix, Inc. stock logo
BDSX
Biodesix
-$35.26M-$4.06N/AN/AN/A-33.26%-2,101.40%-35.65%8/6/2026 (Estimated)
LifeMD, Inc. stock logo
LFMD
LifeMD
$14.35M$0.0594.0226.11N/A2.37%-150.88%-22.59%8/5/2026 (Estimated)
KindlyMD, Inc. stock logo
NAKA
KindlyMD
-$52.23M-$43.20N/AN/AN/A-7,397.12%-81.32%-54.17%N/A
Exagen Inc. stock logo
XGN
Exagen
-$19.95M-$0.89N/AN/AN/A-29.49%-94.37%-28.96%8/4/2026 (Estimated)

Latest NAKA, LFMD, BDSX, and XGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
KindlyMD, Inc. stock logo
NAKA
KindlyMD
N/A-$0.38N/A-$0.38N/A$2.68 million
5/11/2026Q1 2026
Exagen Inc. stock logo
XGN
Exagen
-$0.24-$0.17+$0.07-$0.17$16.41 million$17.31 million
5/6/2026Q1 2026
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.14-$0.20-$0.06-$0.20$48.84 million$50.16 million
5/4/2026Q1 2026
Biodesix, Inc. stock logo
BDSX
Biodesix
-$1.1298-$0.81+$0.3198-$0.81$23.12 million$25.56 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biodesix, Inc. stock logo
BDSX
Biodesix
N/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
N/AN/AN/AN/AN/A
KindlyMD, Inc. stock logo
NAKA
KindlyMD
N/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biodesix, Inc. stock logo
BDSX
Biodesix
5.09
2.82
2.82
LifeMD, Inc. stock logo
LFMD
LifeMD
N/A
1.04
0.98
KindlyMD, Inc. stock logo
NAKA
KindlyMD
N/A
0.25
0.25
Exagen Inc. stock logo
XGN
Exagen
1.67
3.47
3.47

Institutional Ownership

CompanyInstitutional Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
20.96%
LifeMD, Inc. stock logo
LFMD
LifeMD
35.52%
KindlyMD, Inc. stock logo
NAKA
KindlyMD
N/A
Exagen Inc. stock logo
XGN
Exagen
75.25%

Insider Ownership

CompanyInsider Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
23.20%
LifeMD, Inc. stock logo
LFMD
LifeMD
18.40%
KindlyMD, Inc. stock logo
NAKA
KindlyMD
24.49%
Exagen Inc. stock logo
XGN
Exagen
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biodesix, Inc. stock logo
BDSX
Biodesix
22010.36 million7.95 millionNo Data
LifeMD, Inc. stock logo
LFMD
LifeMD
23048.36 million39.46 millionOptionable
KindlyMD, Inc. stock logo
NAKA
KindlyMD
N/A17.40 million13.14 millionN/A
Exagen Inc. stock logo
XGN
Exagen
22024.16 million21.65 millionOptionable

Recent News About These Companies

Exagen (NASDAQ:XGN) Stock Price Up 4.2% - Here's Why
Exagen Earnings Call Highlights Growth Amid Key Risks
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Inc. Reports First Quarter 2026 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biodesix stock logo

Biodesix NASDAQ:BDSX

$15.06 +0.26 (+1.76%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$15.22 +0.15 (+1.03%)
As of 06/12/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

LifeMD stock logo

LifeMD NASDAQ:LFMD

$4.70 -0.20 (-4.08%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$4.77 +0.07 (+1.57%)
As of 06/12/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

KindlyMD stock logo

KindlyMD NASDAQ:NAKA

$4.32 -0.15 (-3.36%)
As of 06/12/2026 04:00 PM Eastern

Kindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.

Exagen stock logo

Exagen NASDAQ:XGN

$4.67 +0.19 (+4.24%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$4.68 +0.00 (+0.11%)
As of 06/12/2026 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.